Phase 3 study of ONT-380 in combination with Kadcyla in patients with CNS metastases
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2015
At a glance
- Drugs Tucatinib (Primary) ; Trastuzumab emtansine
- Indications Brain metastases
- Focus Therapeutic Use
- Sponsors Cascadian Therapeutics
- 11 Dec 2015 Status changed from not stated to planning.
- 11 Dec 2015 New trial record
- 08 Dec 2015 According to Oncothyreon media release,company is planning to discuss about the designs of this trial, together with the overall registration strategy, with the regulatory authorities that includes the US FDA, in the first part of 2016.